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ABSTRACT

A non-human transgenic mammalian animal, as described
above, contains an exogenous double Stranded DNA
Sequence Stably integrated into the genome of the animal,
which comprises cis-acting regulatory units operably linked
to a DNA sequence encoding human Factor VIII protein and
a signal peptide, where the cis-acting regulatory units are
active in mammary gland cells and the Signal peptide is
active in directing newly expressed Factor VIII into the milk
of the animal. The promoter may be a milk protein promoter
Such as for whey acidic protein, casein, lactalbumin, or
beta-lactoglobulin promoter. The transgenic mammals are
preferably farm animals, for example, cows, goats, sheep,
rabbits and pigs. Concurrent expression of a gene for human
von Willebrand's Factor into milk may be used to stabilize
newly-secreted Factor VIII.
42 Claims, 3 Drawing Sheets
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TRANSGENIC MAMMALS EXPRESSING
HUMAN COAGULATION FACTOR VIII
BACKGROUND OF THE INVENTION

This invention relates generally to transgenic animals and
their use as bioreactors for the production of clinically useful
quantities of proteins. More Specifically, this invention
relates to a non-human transgenic animal genetically engi
neered to express recombinant human Factor VIII protein or
von Willebrand Factor protein and to secrete newly
expressed protein into a body fluid from which the protein
can readily be isolated.

5

Factor VIII (“F8”) is a blood plasma glycoprotein of about
260 kDa molecular mass produced in the liver of mammals.
It is a critical component of the cascade of coagulation
reactions that lead to blood clotting. Within this cascade is
a step in which Factor IXa, in conjunction with F8, converts

15

(1989), expressed recombinant F8 in transformed CHO

Factor X to an activated form, Factor Xa. F8 acts as a

Until recently, the standard treatment of Hemophilia A
involved frequent infusions of preparations of F8 concen
trates derived from the plasmas of human donors. While this
replacement therapy is generally effective, Such treatment
puts patients at risk for virus-transmissible diseaseS Such as
hepatitis and AIDS. Although this risk has been reduced by
further purification of F8 from plasma by immunopurifica
tion using monoclonal antibodies, and by inactivating
Viruses by treatment with either an organic Solvent or heat,
Such preparations have greatly increased the cost of
treatment, and are not without risk. For these reasons,

patients have been treated episodically, rather than prophy
lactically. A further complication is that about 15% of
patients develop inhibitory antibodies to thus-prepared F8.
An important advance in the treatment of Hemophilia A
has been the isolation of cDNA clones encoding the com

plete 2,351 amino acid sequence of human F8 (see, Wood et
al, Nature, 312:330 (1984) and U.S. Pat. No. 4,757,006, Jul.
12, 1988) and the provision of the human F8 gene DNA
Sequence and recombinant methods for its production).

cells, but production and Secretion of newly Synthesized
protein into the conditioned growth medium was very low.
This was Said to have been due to three factors: a require
ment for the presence of the VWF in the conditioned medium
used in these culture Systems in order to protect newly
25
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(1992). Physiological activation of the heterodimer occurs

(producing 6,000 L of milk yearly), 10 goats, sheep or pigs
(producing 500 L of milk yearly), or 5,333 rabbits
(producing 0.9 L of milk yearly) would be more than
(Paleyanda et al., above).

55

kDa protein, and thence to 54 kDa and 44 kDa fragments.
Thrombin also cleaves the 80 kDa light chain to a 72 kDa
protein. It is the latter protein, and the two heavy chain

SUMMARY OF THE INVENTION

It is therefore an object of this invention to provide a
non-human, transgenic female mammalian animal that pro

fragments (54 kDa and 44 kDa above), held together by

duces F8.
60

when the 72 kDa and 54 kDa proteins are further cleaved by
thrombin, activated protein C or Factor Xa. In plasma, this
F8 complex is stabilized by association with a 50-fold

It is another object of the invention to provide a process
for producing transgenic mammals with the aforementioned
characteristic.

excess of von Willebrand Factor protein (“vWF"), which
appears to inhibit proteolytic destruction of F8.
The amino acid Sequence of F8 is organized into three
structural domains: a triplicated A domain of 330 amino

units per year. At a specific activity of 5,000 U/mg, about
120 g a year are required. ASSuming an achievable expres
Sion level of 50 mg/L in the milk of a transgenic animal of
the invention and a 50% loss of the protein during
purification, it has been estimated that about 1 cow
sufficient to supply all of this country's needs for F8

through proteolytic cleavage of the protein chains by throm

calcium ions, that constitute active F8. Inactivation occurs

of a post-translational event. Stable recombinant F8 was
secreted by CHO cells only when the gene for VWF was
concurrently expressed. Additional drawbacks to the use of
mammalian tissue culture Systems for the production of F8
in clinically useful quantities are the expense of growth
media and the limited production capacity of mammalian
tissue culture Systems.
An important need remains for an efficient and relatively
inexpensive means of producing large quantities of infec
tious particle-free, human F8 protein Suitable for clinical
use. The transgenic animal System described below that
produces human F8 recombinantly Satisfies this need.
It has been estimated, for example, by Paleyanda et al., in
RECOMBINANT TECHNOLOGY IN HEMOSTASIS

human F8 determined from the cloned cDNA indicates that

bin (Factor IIa). Thrombin cleaves the heavy chain to a 90

secreted F8 from proteolytic destruction (in the absence of
were Subsequently degraded); incomplete Secretion of newly
synthesized F8 from the cells (most remained in the endo
plasmic reticulum); and, a low level of F8 mRNA as a result
v WF, Factor VIII was secreted as incomplete chains that

AND THROMBOSIS eds., Hoyer et al., (Plenum Press,
N.Y. 1991), that the U.S. market for F8 is about 600,000,000

Analysis of the deduced primary amino acid Sequence of
it is a heterodimer processed from a larger precursor
polypeptide. The heterodimer consists of a C-terminal light
chain of about 80 kDa in a metal ion-dependent association
with an about 210 kDa N-terminal heavy chain fragment.
See review by Kaufman, Transfusion Med. Rev.S., 6: 235

Wood et al. 1984, above transfected transformed hamster

kidney cells with a vector containing a gene that encodes F8,
and expressed this protein. Kaufman, Nature 342: 207

cofactor at this step, being required with calcium ions and
phospholipid for the activity of Factor IXa. The two most
common hemophilic disorders are caused by a deficiency of

functional F8 (Hemophilia A, about 80% of all cases) or
functional Factor IXa (Hemophilia B or Christmas Factor
disease).

2
acids, a Single B domain of 980 amino acids, and a dupli
cated C domain of 150 amino acids. The B domain has no
homology to other proteins and provides 18 of the 25
potential asparagine(N)-linked glycosylation sites of this
protein. Although porcine and human F8 show Striking
divergence in their B domains, the porcine protein can be
used to treat Hemophilia A in humans. This Suggests either
that the B chain is not critical to the biological activity of the
holomolecule, or that multiple versions of this domain are
similarly effective. Porcine and human F8 show 80-85%
homology in two of the three A domains.
Although the hepatocyte is likely to be the cell type that
produces F8 in Vivo, to date there are no known natural cell
lines that express this protein. Kaufman, 1992, above, and

65

It is still another object of the invention to provide a
method for producing F8 in commercially valuable amounts,
by inducing a non-human transgenic female mammal to
Secrete expressed F8 into its milk, and isolating this protein
from the milk.

5,880,327
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Stages of development, including embryonic and fetal
Stages. A “transgenic' animal is any animal containing cells
that bear genetic information received, directly or indirectly,
by deliberate genetic manipulation at the Subcellular level,
Such as by microinjection or infection with recombinant

3
It is yet another object to provide a transgenic animal that
has had stably integrated into its genome DNAS encoding
both F8 and v WF, such that both proteins are expressed and
Secreted into the animal's milk.

These objects have been realized by the production of a
non-human transgenic female mammalian animal into
whose genome is stably integrated an exogenous recombi
nant double Stranded DNA sequence comprising a protein
promoter Specifically active in a Secretory gland operably
linked to a DNA sequence encoding F8 or vWF or both
proteins and a Signal peptide effective in directing Secretion
of newly expressed F8 protein into a body fluid of the
animal. More particularly, the protein promoter is for a milk
protein and the Signal peptide directs the expressed F8 into
the animal’s milk.

These objects are also realized by the provision of double
Stranded DNA constructs comprising a tissue-specific active
protein promoter operably linked to a DNA sequence encod
ing F8 or VWF and a DNA sequence encoding a signal
peptide that directs newly expressed F8 or VWF into the host
animal's body fluid, which constructs are used to produce
the transgenic animal.
Other objects, features and advantages of the present
invention will become apparent from the following detailed
description and the appended claims. It should be
understood, however, that the detailed description and
examples given below, while indicating preferred
embodiments, should not be considered limiting in any way
as various changes and modifications within the Spirit and
Scope of the invention will become apparent to the skilled
artisan from this detailed description.

WUS.

“Transgenic’ in the present context does not encompass
classical crossbreeding or in vitro fertilization, but rather
denotes animals in which one or more cells receive a

15

The information to be introduced into the animal is

preferably foreign to the Species of animal to which the

recipient belongs (i.e., "heterologous'), but the information
25

invention.
35

(“WAP) genomic sequences. The 14.6 kb insert, composed

of a 2.6 kb 5’ WAP gene, a 7.5 kb human F8 cDNA and a 4.6
kb 3WAP gene, can be excised by Not I digestion of the
plasmid, releasing the 2.1 kb pPoly III D vector.
FIG. 2 is a Schematic representation of the production of
a mouse WAP-Human F8 cDNA hybrid gene, showing the
insertion of a 7.5 kb human F8 cDNA at the Kpn I site of the
mouse WAP gene, in the p225.11 plasmid.
FIG. 3 is a sketch showing a Western blot of separated
milk whey proteins obtained from transgenic mice induced
to express human F8 into their milk. The first lane on the left
shows molecular weight markers. The next lane shows
authentic human F8 with major bands at about 80 kDa and
about 210 kDa. The next lane shows the proteins in control
whey. Lanes marked F2 and F3 show the proteins in the
whey of transgenic mice induced to express recombinant

40

There has been invented a non-human transgenic female
mammalian animal into whose genome is stably integrated
an exogenous DNA sequence comprising a milk protein
promoter Specifically active in mammary gland cells oper
ably linked to a DNASequence encoding a human F8 protein
and a signal Sequence effective in directing Secretion of
newly expressed F8 protein into the milk of the transgenic
animal.
The term “animal’ here denotes all mammalian animals

except humans. It also includes an individual animal in all

It is highly preferred that a transgenic animal of the
present invention be produced by introducing into Single cell
embryos appropriate polynucleotides that encode human F8
or v WF, or fragments or modified products thereof, in a
manner Such that these polynucleotides are stably integrated
into the DNA of germ line cells of the mature animal, and
are inherited in normal mendelian fashion.

45

Advances in technologies for embryo micromanipulation
now permit introduction of heterologous DNA into fertilized
mammalian ova. For instance, totipotent or pluripotent Stem
cells can be transformed by microinjection, calcium phos
phate mediated precipitation, lipoSome fusion, retroviral
infection or other means, the transformed cells are then

50

human F8.
DETAILED DESCRIPTION OF THE
INVENTION

may also be foreign only to the particular individual
recipient, or genetic information already possessed by the
recipient. In the last case, the introduced gene may be
differently expressed than is the native gene.
The transgenic animals of this invention are other than
human, and produce milk, blood Serum, and urine. Farm

animals (pigs, goats, sheep, cows, horses, rabbits and the
like), rodents (Such as mice), and domestic pets (for
example, cats and dogs) are included in the Scope of this

DESCRIPTION OF THE FIGURES

FIG. 1 is a schematic representation of a human F8 cDNA
construct showing the contribution of whey acid protein

recombinant DNA molecule. Although it is highly preferred
that this molecule be integrated within the animal's
chromosomes, the invention also encompasses the use of
extrachromosomally replicating DNA sequences, Such as
might be engineered into yeast artificial chromosomes.
The term “germ cell line transgenic animal' refers to a
transgenic animal in which the genetic information has been
taken up and incorporated into a germ line cell, therefore
conferring the ability to transfer the information to offspring.
If Such offspring, in fact, possess Some or all of that
information, then they, too, are transgenic animals.

55

60

65

introduced into the embryo, and the embryo then develops
into a transgenic animal. In a highly preferred method,
developing embryos are infected with a retrovirus contain
ing the desired DNA, and transgenic animals produced from
the infected embryo. In a most preferred method, however,
the appropriate DNAS are coinjected into the pronucleus or
cytoplasm of embryos, preferably at the Single cell Stage,
and the embryos allowed to develop into mature transgenic
animals. Those techniques as well known. See reviews of
Standard laboratory procedures for microinjection of heter
ologous DNAS into mammalian fertilized ova, including
Hogan et al., MANIPULATING THE MOUSE EMBRYO,

(Cold Spring Harbor Press 1986); Krimpenfort et al., Bio/
Technology 9:844 (1991); Palmiter et al., Cell, 41: 343
(1985); Kraemer et al., GENETIC MANIPULATION OF
THE EARLY MAMMALIAN EMBRYO, (Cold Spring
Harbor Laboratory Press 1985); Hammer et al., Nature, 315:
680 (1985); Wagner et al., U.S. Pat. No. 5,175,385;
Krimpenfort et al., U.S. Pat. No. 5,175,384, the respective
contents of which are incorporated by reference.

5,880,327
6

S
Human F8 cDNA can be obtained by isolating it from an

introducing mutations into the cloned genes by, for example,
oligonucleotide-mediated mutagenesis.
The cis-acting regulatory regions useful in the invention
include the promoter that drives expression of the F8 or
Subunit chain genes. Highly preferred are promoters that are
Specifically active in mammary gland cells and that involve
milk proteins. Among Such promoters, highly preferred are
the Short and long WAP, short and long C, B and kappa

appropriate genomic Source (i.e., human liver which is the
natural organ for production of this protein) by alternate

methods which include preparation of cDNAs from isolated
mRNA templates, direct Synthesis, or Some combination
thereof, as described by Wood et al. 1984 above, and Toole
et al. U.S. Pat. No. 4,757,006, which are incorporated by
reference.

casein, C.-lactalbumin and B-lactoglobulin (“BLG”) promot

The cDNAs encoding F8 or vWF or individual fragments
or modified proteins thereof can be fused, in proper reading
frame, with appropriate regulatory Signals as described in
detail below, to produce a genetic construct that is then

amplified, for example, by preparation in a bacterial (e.g., E.
coli) plasmid vector, according to conventional methods.

See Sambrook et al., Molecular Cloning. A Laboratory

CS.

15

Manual (Cold Spring Harbor Press 1989), the contents of

which are incorporated by reference. The amplified con
struct is thereafter excised from the vector and purified for
use in producing transgenic animals. Purification can be
accomplished by means of one or more cycles of anionic
HPLC, alternate techniques include ultracentrifugation
through a Sucrose or NaCl gradient, gel electrolution fol
lowed by agarose treatment and ethanol precipitation, or low
preSSure chromatography. Purification by Several cycles of
HPLC allows for remarkably high transformation
frequencies, on the order of 20% or more in both mice and
pigs.
Although the present invention preferably entails the use
of DNA constructs that produce the desired or native human
F8 protein or VWF per se, the desired protein also may be
produced as a fusion protein containing another protein. For
example, the desired recombinant protein of this invention
may be produced as part of a larger recombinant protein in
order to Stabilize the desired protein or to make its purifi
cation from milk faster and easier. The fusion partners then
are Separated chemically or enzymatically, and the desired
protein isolated.

Clark et al., TIBTECH 5: 20 (1987), the respective content

25

and Henninghausen, Protein Expression and Purification4

1: 3 (1990), the respective contents of which are incorpo

35

rated herein by reference.
The promoter may be isolated by carrying out conven
tional restriction endonuclease and Subcloning Steps. A
mouse WAP promoter, isolated as a 2.6 kb EcoR1-Kpn1
fragment immediately 5' to the WAP Signal Sequence, is

preferred, although the “long” WAP promoter (the 5' 4.2 kb
Sau 3A-Kpn1 promoter of the mouse WAP gene, or a

fragment thereof) is also Suitable for carrying out this
40

above.

45

invention.

Important to the present invention are regulatory
Sequences that direct Secretion of proteins into milk and/or
other body fluids of the transgenic animal. In this regard,
both homologous and heterologous regulatory Sequences are
useful in the invention. Generally, regulatory Sequences
known to direct the Secretion of milk proteins, Such as either
Signal peptides from milk proteins or the nascent target
polypeptide, can be used, although Signal Sequences can also
be used in accordance with this invention that direct the

50

et al., above.
55

60

Secretion of expressed proteins into other body fluids, par
ticularly blood and urine. Most preferred for the transgenic
mouse are the regulatory Sequences for the WAP protein.
Among the useful Sequences that regulate transcription, in
addition to the promoters discussed above, are enhancers,
Splice Signals, transcription termination signals, and poly
adenylation Sites. Particularly useful in this regard are those
that increase the efficiency of the transcription of the genes
for F8 or VWF in the mammary gland or other cells of the
transgenic animals listed above. Preferred are transcription
regulatory Sequences for proteins highly expressed in the

mammary gland cells (see above).

context include, but are not limited to, those that alter

post-translational modifications, size or active Site, or that
fuse this protein or portions thereof to another protein. Such
modifications can be introduced into the protein by tech
niques well known in this art, Such as by Synthesizing
modified genes by ligation of overlapping oligonucleotide or

equine and Ovine (pigs, sheep, goats, cows, horses), rabbits,
rodents and domestic pets (dogs and cats). The genes for
these promoters have been isolated and their characteriza

having the identical Sequence as the native molecule, or it
may be produced as a fragment or derivative. A variety of
modified rhE8 or subunits thereof can be produced by
altering a cloned DNA using the well-known techniques of
in vitro mutagenesis Such as those Set out in the references

DNA constructs useful in the present invention provide a
double stranded DNA sequence encoding rhE8 or rhvWF
operably linked to all of the cis-acting Signals necessary for
mammary gland-Specific expression of this protein, post
translational glycosylation and Secretion of the protein into
milk or other body fluids, and expression of full biological
activity.
Modified F8 or v WF DNA sequences also can be
employed in this invention. Useful modifications within this

of which are incorporated herein by reference. Preferred
among the promoters for carrying out the present invention
are the rodent casein and WAP promoters, and the casein,
C.-lactalbumin and BLG promoters from porcine, bovine,

tions published. For reviews see Clark et al. (1987), above,

Recombinant human F8 (“rhF8”) may also be produced

Production of transgenic animals containing the gene for
rhF8 involves the use of cDNA or genomic DNA that
encodes the precursor protein or heterodimeric rhE8. The
full length base Sequence of each protein chain is disclosed
in the aforementioned publication of Wood et al. and Toole

Promoters may be selected on the basis of the protein
compositions of various milks. For example, the WAP and
BLG promoters are particularly useful with transgenic
rodents, pigs and sheep. The rodent WAP short and long
promoters have been used to express the rat WAP gene, the
human tPA gene and the CD4 gene, while the sheep BLG
promoter has been used to express the sheep BLG gene, the
human alpha-1-antitrypsin gene and the human Factor IX
gene. For reviews see Paleyanda et al., 1991, above, and

65

Preferably, the expression system or construct of this
invention also includes a 3' untranslated region downstream
of the DNA sequence encoding the desired recombinant
protein, or the milk protein gene used for regulation. This
region apparently Stabilizes the RNA transcript of the
expression System and thus increases the yield of the desired

5,880,327
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7
protein. Among the 3' untranslated regions useful in this
regard are Sequences that provide a poly A Signal. Such
Sequences may be derived, e.g., from the SV 40 Small t
antigen, the casein 3' untranslated region, or other 3' untrans
lated sequences well known in this art. Preferably, the 3'
untranslated region is derived from a milk-specific protein.

By means of techniques described above, F8-encoding
cDNA can be inserted into an ovine BLG gene. For instance,
in order to produce Such a construction, the 11.2 Kbp Ovine
BLG gene may be modified to possess a unique EcoRV site
upstream of the initiator ATG codon in the vector puCX
SRV. The Sequence around this region is changed as follows:
Pv

Seq. ID No. 1

Natural

Seq. ID No. 2

pUCXSRV

Met Lys

CCCCAGCT GCAGCCAT GAAG

EcoRV

The Stabilizing effect of this region's poly A transcript is
important in stabilizing the mRNA of the expression
Sequence. Also important in increasing the efficiency of
expression of F8 are ribosome binding Sites. Likewise,
Sequences that regulate the post-translational modification

15

of F8 are useful in the invention.

Thus, in accordance with this invention, a double

Stranded chimeric DNA including genes encoding the F8 or
VWF proteins or both, operably linked to cis-acting regula
tory Sequences that promote efficient expression of the
former in milk and/or other body fluids are introduced into
an embryo where they are integrated into the embryonic
genome and become part of the inheritable genetic endow
ment of all of the animals cells, including the germline cells,
of the adult that matures from the embryo. The recombinant
proteins thus expressed and Secreted into milk are immu
nologically reactive, as can be measured by an ELISA assay

25

promoter sequences (pUCSV). As with puCSRV, blunt
35

40

peptide sequences (FIGS. 1 and 2). A native 5'-WAP regu
latory Sequence ending in an accessible restriction site
immediately before/at the ATG codon may be ligated to the

45

restriction sites that occur at the ATG of translatable

Sequences with no linker Sequences derived from the chains
of human F8. Each of the combined 5'-regulatory and F8
translatable Sequences ending in a particular restriction site
may then be ligated to a corresponding restriction site which
occurs at the beginning of the 3'-untranslated region of WAP
and adjoining WAP 3'-flanking region. This construction
motif enables native 5'-regulatory and 3'-UTR of the milk
protein genes to be immediately juxtaposed without inter
vening Sequences. Particular restriction Sites at the ends of
all constructs may be selected in order to facilitate concat
enation of constructs into a single domain within the animal

50

55

genome.

Although the above general descriptions of the DNA
constructs of the invention have been given in terms of the
WAP promoter, it is emphasized that other suitable promot

60

ers (see above for discussion) may be ligated to the Factor

VIII encoding polynucleotides in a similar manner. By way
of illustration, the following discussion describes the use of
the BLG promoter to increase the efficiency of expression of
F8 and F8-BLG fusion proteins in mammary glands.

blunt ends are generated with T4 DNA polymerase, and the
product is ligated to EcoRV-cleaved puCXSRV. Following
transformation of E. coli with this plasmid, clones that are
produced can be characterized by restriction analysis of
plasmid DNA prepared by a mini-prep method and by
determination of the nucleotide Sequence around the 5' and
3' cloning junctions for the DNA. Clones having the desired
Structure can be used to produce transgenic rodents, pigs,
sheep, cows, horses and other farm animals and domestic
into their biological fluids as described below.
A human F8 genomic Sequence also may be fused to the
ovine BLG promoter illustrated in the following discussion.
DNA sequences encoding ovine BLG in plasmid puCXSRV
are deleted to generate a vector containing only Ovine BLG

Sequences.

In a particularly preferred embodiment, the transgenes of
the invention generally consist of WAP milk protein
upstream and downstream flanking the F8 cDNA?signal

This allows the cloning of blunt end fragments upstream

of the BLG gene. The 7.5 kbp fragment from a plasmid (e.g.,
p122, FIG. 2) containing a CDNA encoding hF8 is isolated,

pets (cats and dogs) that Secrete a F8-BLG fusion product

to be described below.

Where the synthesis of a F8 subunit chain may be limiting
in the production of the holoprotein, expression of this chain
can be increased by placing the gene in a different genomic
locus. This other locus can contain a DNA sequence under
the same or a different regulatory Sequence than other

Met Lys

CCCCAGGGATATCCCTG CAGCCAT GAAG

65

ended fragments may be fused to this promoter region by
ligation to a unique EcoRV site. The Sequences 5' to this site
are identical in both plasmids.
Genomic F8 Sequences of greater than about 15 kbp can
be introduced into transgenic animals, despite their length,
through the use of cosmids with overlapping F8 Sequences,
whereupon the necessary assembly of an entire genomic
polynucleotide encoding hE8 is achieved by homologous
recombination in Vivo after microinjection into an embryo
cell. In constructs useful in the foregoing example, a plasmid
in which the F8 genomic sequences are fused to ovine BLG
3' flanking Sequences just after the F8 translation termination
codon to ensure proper transcription, termination and poly
adenylation. The hE8 gene fused to ovine BLG 3' flanking
Sequences is excised from the plasmid, the 3' overhangs
repaired using Klenow enzyme, and the product ligated to
EcoRV-cleaved puCSR. Following transformation of E.
coli, the resulting clones are characterized by restriction
DNA analysis and by determining the nucleotide Sequences
around the 5' and 3' cloning junctions. Clones having the
desired Structure may be introduced into fertilized animal
ova for production of transgenic animals.
A variety of vectors based on the BLG gene may be
constructed. In constructs based on this approach, the
Sequences encoding the Ovine BLG protein are deleted, but
the 5' promoter Sequences are retained. Each may possess a
different complement of introns from the Ovine gene and a
unique EcoRV site allowing the cloning of blunt ended
fragments between the promoter and 3’ flanking region of
the gene. However, each contains the BLG promoter, the
EcoRV site and the BLG 3'-flanking sequence. For each
recombinant, the 7.5 kbp KpnI fragment from p122 is
isolated, blunt ends generated as above, and the product
ligated to EcoRV-cleaved vector Sequences. Those con

5,880,327
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Structs with the proper structures (determined as described
above) may be used to express F8 in the biological fluids of

10
EXAMPLE 1.

transgenic animals.
Doubly-transgenic mice which have native BLG genomic
Sequences that are injected as Separate constructs to be
concatenated in Vivo as additional flanking Sequences to the

Construction of mWAP-hF8 cDNA Hybrid Gene

A pPoly III-D vector (p120 in FIG. 2) was restricted with

Kpn 1, blunt ended and religated to produce vector A
without a Kpn 1 site.
A 7.2 kb mWAP gene was excised from the p121 plasmid
with Eco R1, blunted, and ligated into Vector A that was
linearized with Eco R1. The product was a 9.3 kb plasmid

BLG target clDNA construct (such as, BLG promoter-Intron
I-EcoRV-Intron VI-BLG 3' flank plus BLG) give higher
expression more frequently than that observed with the use
of constructs of the BLG promoter-F8 cDNA-BLG gene or
BLG promoter-F8 genomic (tPLG 3' end). Intact or native
BLG genomic Sequences that are preligated to the BLG
cDNA target may give the same advantage. This same
principle can be extended to WAP genomic Sequences.
Obtaining milk from a transgenic animal according to the
present invention is accomplished by conventional means.
See, e.g., McBurney et al., J. Lab. Clin. Med. 64: 485

(labeled p184) in which the WAP gene was flanked by Eco

15

(1964); Velander et al., Proc Natl. Acad. Sci. USA 89:12003
(1992), the respective contents of which are incorporated by

reference. F8 or VWF or fragments thereof or protein prod
ucts thereof can be isolated and purified from milk or urine
by conventional means without deleteriously affecting activ
ity. A preferred method consists of a combination of anion
eXchange and immu no chromatographie S,
cryoprecipitations, Zinc ion-induced precipitation of either

whole milk or milk whey (defatted milk) proteins. For these
techniques, see Bringe et al., J. Dairy Res. 56: 543 (1989),

25

Type Culture Collection, Rockville, Md. (ATCC Accession
No. 97777). Applicants hereby provide assurances that: (1)
during the pendency of this patent application access to the
deposited plasmids will be made available to perSons prop
erly designated by the Commissioner of Patents and Trade

the contents of which are incorporated herein by reference.
Milk is known to contain a number of proteases that have
the potential to degrade foreign proteins. These include in
the main an alkaline protease with tryptic and chymotryptic
activities, a Serine protease, a chymotrypsin-like enzyme, an

marks; (2) Subsequent to the issuance of this patent, the
plasmids will be made available to the public without
restriction for the enforceable life of the patent, or for five
years after the last request for a sample, or for thirty years,

aminopeptidase and an acid protease. Clark et al. (1987)

above. It may be desirable therefore to protect newly
Secreted F8 or fragments thereof against proteolytic degra
dation. Such precautions include rapid processing of the

R1 and adjacent Not 1 restriction sites.
Partial digestion of plasmid p122 with Kpn 1 produced a
7.5 kb F8 cDNA flanked by Kpn 1 restriction sites. This
cDNA was then inserted into plasmid p184 at a Kpn 1 site
within the mWAP gene to produce plasmid p225.11, a 16.8
kb plasmid. Flanking the human F8 gene is a 2.6 kb 5’mWAP
segment with an upstream Not 1 site, and a 4.6 kb 3' mWAP
gene with a downstream Not 1 site.
As shown in FIG. 1, the 14.7 kb insert comprising the 5'
mWAP/hF8/3' mWAP hybrid gene can be excised by Not 1
digestion of the p225.11 plasmid, thereby releasing the 2.1
kb pPoly III-D vector.
The p225.11 plasmid has been deposited in the American

35

whichever is longest; and, (3) nonviable plasmids will be
replaced.

milk after collection and addition to the milk of well known

EXAMPLE 2

inhibitors of proteolysis, such as are listed in SIGMA

CHEMICAL CO. CATALOG (1993 edition) at page 850,

the contents of which are incorporated herein by reference.
As discussed above, under physiological conditions v WF
complexes with circulating F8 and stabilizes the latter from
degradation. In the present invention, the cDNA for v WF,
which is available from the American Type Culture
Collection, Rockville, Md. may be assembled into a con

40

of recombinant human Factor VIII (recombinant human F8)
45

struct similar to that described in FIGS. 1 and 2 and

microinjected into an embryo concurrently with the F8
construct. Under such conditions, both proteins will be
expressed and Secreted into the milk.
For determination of newly secreted F8 and/or v Wif in
milk whey, we have used the immunoradiometric assays
essentially according to Hoyer et al., Methods Enzymol. 84:

50
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Whey, mouse f2.1.9.10
Whey, mouse f2.13.9
Whey, mouse f2.1.13.13
Whey, mouse f2.1.22.8
Whey, control mouse D15
AS referenced above, an immunoradiometric assay

(IRMA) was performed as described in Hoyer et al., Meth
Ods in Enzymol. 84: 51-60 (1982). Iodinated anti-human

Factor VIII Fab' fragments were used to detect recombinant
Factor VIII in milk.
60

Reagents
Borate-buffered saline, pH 7.85

Non-immune human IgG (Sigma)
Heparin stock at 2000 U/ml, in borate saline buffer

Solutions.

The following examples are provided merely to illustrate
the invention, and are not to be interpreted as limiting the
Scope of the invention which is described in the Specification
and appended claims.

in the milk whey of transgenic mice produced with the
mWAP promoter system described above by the following
procedure.
Materials

51,56-57 (1982), which is incorporated herein by reference.

F8 antigens are measured with an radioiodinated human
anti-F8 Fab' inhibitor antibody derived from patients with
autoantibodies or transfused hemophiliac patients who have
developed inhibitors. VWF antigens are measured with rab
bit antibodies obtained by immunization with purified F8.
Both assays use radiolabeled antibody that has been purified
from immune complexes. Antigen measurement in these
assays is based on the differential Solubility of the antigen
antibody complexes and free antibody in ammonium Sulfate

Assay for Factor VIII Protein in Milk Whey by an
IRMA Assay
The IRMA assay was used to estimate the concentration

Normal pooled plasma (NPP)
65

ARC iodinated Fab' fragments in borate saline with 1
mg/ml BSA
Ammonium Sulfate

5,880,327
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Procedure

Thrombin: 2 units/mL

1) Heparin was diluted to 4 U/ml in 2% non-immune

TBS: 20 mM Tris, 500 mM NaCl, pH 8.0

2) A standard curve with serial dilutions of NPP (1:2 to
1:128) was set up, with buffer as the blank. All stan

TBS/T/NFDM TBS/T with 5% Non-fat dry milk
Primary antibody in 1x TBS/T/NFDM:

human IgG as a carrier protein in buffer.

TBS/T TBS with 0.05% Tween 20

dards and Samples were assayed in duplicate.

Monoclonal antibody 413 (2 tug/ml; anti-heavy chain)
Monoclonal antibody 37 (5ug/ml; anti-light chain)

3) To 12x75 mm polystyrene tubes were added the
following:
50 it 2% non-immune human IgG
50 uL NPP buffer or test milk whey samples

1O

50 uAL of 'I-labeled Fab' fragments (about 1000

System (Boerhringer-Mannheim)
Procedure
15

5) 200 uL of a 95% solution of ammonium sulfate was
added and incubated at room temperature for 30 min

1) Whey samples (200 ug total protein) were digested
with thrombin (130 uU?ul ) for 5 minutes. An equal
volume of 2x Sample Buffer was added and samples
were boiled for 5 minutes, and quickly cooled on ice.

uteS.

6) The tubes were centrifuged at 2,800 rpm at room

2) Samples were run on 1.2 mm-thick 7.5% acrylamide

temperature for 30 minutes. The pellet was washed

Laemmli gel. Proteins were electroblotted onto nitro

twice with 1 mL of a 38% ammonium Sulfate Solution

cellulose membrane at 12 volts for 1.5 hours. The
membrane was stored in TBS at 4 C.

and recentrifuged as above for 20 minutes.

7) The Supernatant was decanted and the pellets assayed
for residual radioactivity in a gamma-counter. ASSay
values were determined by reference to the Standard

Streptavidin, alkaline phosphatase conjugate (GIBCO)
LumiPhoS Luminescent Biotin-conjugated Development

cpm)
4) Tubes were vortexed and incubated in a 37° C. water

bath for 2 hours, to allow complex formation between
Fab' and Factor VIII antigen.

Secondary antibody diluted 1:6000 in 1x TBS/T

25

3) The membrane was blocked in TBS/T/NFDM for 1
hour and washed 3 times in TBS/T.

CWC.

4) Primary antibody was added to the membrane for 2

The results of IRMA tests are shown in the table below.

hours at 25 C., then washed 3 times in TBS/T.

5) The membrane was incubated in secondary antibody
for 15 minutes at 25°C., then washed 4 times in TBS/T.

Factor VIII

PDL Designation

Sample vol.*

antigen

6) The membrane was incubated in LumiPhos according

Mouse ID no.

ful

units/ml

ng/ml

Control D15
F2.1.13.9
F2.1.9.10
F2.1.22.8
F2.1.13.13

1OO
1OO
50
40
50

O.O41
O.O45
O.1OO
0.144
O.O93

8.2
9.O
2O.O
28.8
18.6

*Samples stored at -20°C. In 2 animals, storage of the milk at 4 C. led to
reduced values a recombinant human FV III.

to manufacturer's directions for 20 minutes in the dark.
35

CCSSO.

markers from 45 to 200 kDa. The second from the left lane
40

is standard hE8 showing a major band at about 80 kDa and

45

control whey proteins. The F2 and F3 lanes show transgenic
milk wheys, there were Strongly staining new bands at about
80 kDa, compared to the control, in parallel to the Standard
hF8. The F2 and F3 lanes also show intensely staining bands
at about 120 kDa, a band that is relatively faint in the control
and apparently absent from standard hE8. Its identity is

another at about 210 kDa. The third lane from the left shows

average of about 250% in three of four mice.
Western Blots of Mouse Whey Samples

Milk wheys from two transgenic mice (F2 and F3) were

unknown.

immunoblotted in order to identify recombinant human

Factor VIII (recombinant human F8) in the samples. Western

blots are shown in FIG. 3.

Thrombin Buffer: 0.15M NaCl, 20 mM M HEPES, 5 mM

CaCl, 0.01% Tween 80, pH 7.4

25 minutes. The film was developed in a Kodak pro
The first lane on the left consists of molecular weight

Relative to the background value for this method (control
mouse D15), antigen (F8) production was elevated on an
EXAMPLE 3

7) The membrane was exposed to Kodak XAR-5 film for

50

Taken together, the data of Examples 2 and 3 demonstrate
that the transgenic mice of the invention expressed authentic
recombinant human F8 and secreted this protein into the
animal's milk.

SEQUENCE LISTING

( 1) GENERAL INFORMATION:
( i i i ) NUMBER OF SEQUENCES: 2
( 2) INFORMATION FOR SEQ ID NO:1:
( i) SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 20 base pairs
(B) TYPE: nucleic acid

5,880,327
-continued
(C)STRANDEDNESS: single
(D) TOPOLOGY: linear
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:1:
CCCCAGCTGC

A G C CAT GAA G

2 O

( 2) INFORMATION FOR SEQ ID NO:2:
( i) SEQUENCE CHARACTERISTICS:
( A ) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C)STRANDEDNESS: single
(D) TOPOLOGY: linear
( xi ) SEQUENCE DESCRIPTION: SEQ ID NO:2:
C C C CA. GGG AT

A T C C C T G CAG

C CAT GAA G

We claim:

1. A non-human transgenic mammal that produces in its
mammary gland cells and Secretes into its milk at detectable
levels a recombinant human Factor VIII protein or fragment
or modification thereof having physiological activity of
human Factor VIII, wherein Said transgenic mammal has
Stably integrated into its genome an exogenous gene con
Struct comprising:

28

2O

25

and cattle.

11. The non-human transgenic mammal according to

(A) 5’ expression regulating sequences, including a mam

claim 1, wherein Said mammal is female.

mary gland-Specific promoter;

12. A proceSS for producing recombinant human Factor
VIII protein or fragment thereof having physiological activ
ity of human Factor VIII, comprising the steps of:

(B) DNA encoding said Factor VIII protein or fragment or
modification thereof, and a Signal Sequence effective in
directing Secretion of Said Factor VIII protein or frag
ment thereof into the milk of Said transgenic mammal;
and

9. The non-human transgenic mammal according to claim
1, wherein Said 3' regulatory Sequences are 3' untranslated
regions from a milk protein gene or from a human Factor
VIII gene.
10. The non-human transgenic mammal according to
claim 1, wherein Said transgenic mammal is Selected from
the group consisting of mouse, rat, rabbit, pig, sheep, goat

(a) providing a non-human transgenic mammal having
35

integrated into its genome a an exogenous gene con
Struct comprising:

(C) 3' regulatory sequences, including a polyadenylation

(A) 5’ expression regulating sequences, including a

Signal, that result in the expression of Said DNA in Said
mammary gland cells,

(B) DNA encoding said Factor VIII protein or fragment

mammary gland-specific promoter;

wherein (A), (B), and (C) are operably linked in Said gene

construct to obtain production of said Factor VIII protein or
fragment or modification thereof in Said mammary gland
cells and Secretion thereof into the milk of Said transgenic

40

(C) 3' regulatory Sequences, including a polyadenyla

tion signal, that result in the expression of Said DNA
Sequences in mammary gland cells of Said transgenic

mammal.

2. The non-human transgenic mammal according to claim
1, wherein Said promoter is a milk protein gene promoter.
3. The non-human transgenic mammal according to claim
2, wherein Said milk protein gene promoter is Selected from
the group consisting of whey acidic protein, casein, lactal
bumin and beta-lactoglobulin promoters.
4. The non-human transgenic mammal according to claim
1, wherein said human Factor VIII protein or fragment
thereof is a single chain protein or a multimeric protein.
5. The non-human transgenic mammal according to claim
4, wherein said human Factor VIII protein or fragment
thereof is a single chain protein or a heterodimeric protein
composed of a C-terminal light chain of human Factor VIII
and an N-terminal heavy chain of human Factor VIII.
6. The non-human transgenic mammal according to claim
5, wherein Said C-terminal light chain has a molecular
weight of about 80 kDa and said N-terminal heavy chain of
human Factor VIII has a molecular weight of about 210 kDa.
7. The non-human transgenic mammal according to claim
1, wherein Said transgenic mammal produces human Factor
VIII protein.
8. The non-human transgenic mammal according to claim
7, wherein said human Factor VIII protein has the amino
acid sequence of human Factor VIII.

thereof, and a Signal Sequence effective in directing
secretion of said Factor VIII protein or fragment
thereof into the milk of Said transgenic mammal; and

45

animal,

wherein (A), (B), and (C) are operably linked in Said gene

construct to obtain production of said Factor VIII protein or
fragment thereof in Said mammary gland cells and Secretion
thereof into the milk of Said transgenic mammal,

50

(b) allowing said DNA encoding said Factor VIII protein

or fragment thereof to be expressed and Said Factor
VIII or fragment thereof to be secreted into the milk of
Said transgenic mammal,

55

(c) collecting milk from Said mammal, and,
(d) isolating said Factor VIII protein or fragment thereof
from said milk.

60

65

13. The process according to claim 12, wherein Said
mammal is induced to lactate prior to Said collecting Step.
14. The process according to claim 12, wherein Said
promoter is a milk protein gene promoter.
15. The process according to claim 14, wherein said milk
protein gene promoter is Selected from the group consisting
of whey acidic protein, casein, lactalbumin and beta
lactoglobulin promoters.
16. The process according to claim 12, wherein Said
human Factor VIII protein or fragment or modification
thereof is a Single chain protein or a multimeric protein.

5,880,327
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17. The process according to claim 16, wherein Said
human Factor VIII protein or fragment thereof is a Single
chain protein or a heterodimeric protein composed of a
C-terminal light chain of human Factor VIII and an
N-terminal heavy chain of human Factor VIII.
18. The process according to claim 17, wherein said
C-terminal light chain has a molecular weight of about 80
kDa and said N-terminal heavy chain of human Factor VIII
has a molecular weight of about 210 kDa.
19. The process according to claim 12, wherein Said
transgenic mammal produces human Factor VIII protein.
20. The process according to claim 19, wherein said
human Factor VIII protein has the amino acid Sequence of

27. The proceSS according to claim 26, wherein Said milk
protein gene promoter is Selected from the group consisting
of whey acidic protein, casein, lactalbumin and beta
lactoglobulin promoters.
28. The process according to claim 24, wherein Said
human Factor VIII protein or fragment thereof is a Single
chain protein or a multimeric protein.
29. The process according to claim 28, wherein said
human Factor VIII protein or fragment thereof comprises a
Single chain protein or a heterodimeric protein composed of
a C-terminal light chain of human Factor VIII and an
N-terminal heavy chain of human Factor VIII.
30. The process according to claim 29, wherein said
C-terminal light chain has a molecular weight of about 80
kDa and said N-terminal heavy chain of human Factor VIII
has a molecular weight of about 210 kDa.
31. The process according to claim 24, wherein Said
transgenic mammal produces human Factor VIII protein.
32. The process according to claim 31, wherein Said
human Factor VIII protein has the amino acid Sequence of

human Factor VIII.

21. The process according to claim 12, wherein Said 3'
regulatory Sequences are 3' untranslated regions from a milk
protein gene or from a human Factor VIII gene.
22. The process according to claim 12, wherein Said
transgenic mammal is Selected from the group consisting of
mouse, rat, rabbit, pig, sheep, goat and cattle.
23. The process according to claim 12, wherein Said
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human Factor VIII.

mammal is female.

24. A process for producing a non-human transgenic
mammal that produces in its mammary gland cells and
Secretes into its milk a human Factor VIII protein or frag
ment thereof having physiological activity of human Factor
VIII, comprising the Steps of:

25

(a) providing an exogenous gene construct comprising:
(A) 5’ expression regulating sequences, including a

mammal is female.

mammary gland-specific promoter;

36. The process according to claim 24, wherein Said

(B) DNA encoding said Factor VIII protein or fragment
thereof, and a Signal Sequence effective in directing
Secretion of said Factor VIII protein or fragment
thereof into the milk of Said transgenic mammal, and

(C) 3' regulatory sequences, including a polyadenyla

mammal is male.

37. The process according to claim 12 or 24, wherein said
exogenous gene construct is contained in plasmid p225.11
35

tion signal, that result in the expression of Said DNA
in the milk of Said transgenic mammal,

wherein (A), (B), and (C) are operably linked in Said gene

construct to obtain production of said Factor VIII protein or
fragment thereof in Said mammary gland cells and Secretion
thereof into the milk of Said transgenic mammal;

40

b) introducing the construct of Step (a) into a non-human
mammalian embryo, wherein Said construct is stably
integrated into the genome of Said mammalian embryo,

(c) permitting Said embryo to develop into a non-human

45

transgenic mammal; and
thereof.

construct of step (a) is in the form of DNA, DNA in a vector,

DNA contained in one or more organelles or other parts of
a cell or DNA contained in one or more whole cells.

26. The process according to claim 24, wherein Said
promoter is a milk protein gene promoter.

(ATCC Accession No. 9777).

38. The non-human transgenic mammal according to
claim 1 wherein Said exogenous gene construct comprises
the mouse WAP promoter and gene, and the 3'regulatory
sequence of the WAP gene, wherein human Factor VIII
cDNA is inserted into the Kpn site of the WAP gene.
39. The non-human mammal according to claim 1,
wherein Said exogenous gene construct is contained in

plasmid p225.11 (ATCC Accession No. 9777).

(d) determining that the non-human transgenic mammal
of (c) produces said Factor VIII protein or fragment
25. The process according to claim 24, wherein Said

33. The process according to claim 24, wherein said 3'
regulatory Sequences are 3' untranslated regions from a milk
protein gene or from a human Factor VIII gene.
34. The process according to claim 24, wherein Said
transgenic mammal is Selected from the group consisting of
mouse, rat, rabbit, pig, sheep, goat and cattle.
35. The process according to claim 24, wherein Said
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40. The process according to claim 12 or 24, wherein said
exogenous gene construct comprises the mouse WAP pro
moter and gene, and the 3' regulatory Sequence of the WAP
gene, wherein human Factor VIII cDNA is inserted into the
Kpn site of the WAP gene.
41. Cells obtained from the non-human transgenic mam
mal of claim 1, wherein Said cells have stably integrated into
their genome Said exogenous gene construct.
42. The cells according to claim 41, wherein Said cells
produce said recombinant human Factor VIII protein or
fragments thereof.
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